BRAF inhibitor resistance of melanoma cells triggers increased susceptibility to natural killer cell-mediated lysis

BACKGROUND: Targeted therapies and immunotherapies are first-line treatments for patients with advanced melanoma. Serine–threonine protein kinase B-RAF (BRAF) and mitogen-activated protein kinase (MEK) inhibition leads to a 70% response rate in patients with advanced melanoma with a BRAF(V600E)(/K)...

Descripción completa

Detalles Bibliográficos
Autores principales: Frazao, Alexandra, Rethacker, Louise, Jeudy, Géraldine, Colombo, Marina, Pasmant, Eric, Avril, Marie-Françoise, Toubert, Antoine, Moins-Teisserenc, Helene, Roelens, Marie, Dalac, Sophie, Maubec, Eve, Caignard, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482503/
https://www.ncbi.nlm.nih.gov/pubmed/32912923
http://dx.doi.org/10.1136/jitc-2019-000275

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482503/
https://www.ncbi.nlm.nih.gov/pubmed/32912923
http://dx.doi.org/10.1136/jitc-2019-000275

Ejemplares similares